Clinical trials: Adjuvant Treatment
Breast Cancer, Quality of Life
Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy
The aim of this prospective study is to investigate quality of life and oncologic outcomes in low-risk elderly breast cancer patients randomized to adjuvant therapy with accelerated partial breast irradiation (APBI) alone or…
- Trial name
- CAMERAN (NCT05472792)
- Testing
- Accelerated Partial Breast Irradiation (APBI), tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Major Depressive Disorder, Treatment-Resistant Depression
Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD Patients
In this double-blind, randomized, sham-controlled trial, the investigators aimed to examine the effect of accelerated piTBS on suicide risk in a group of treatment-resistant patients with MDD (i.e., TRD), using an extensive…
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Suicide Ideations
- Trial name
- NCT06372834
- Testing
- piTBS being delivered using the Magstim Rapid2 stimulator
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Breast Cancer
AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer
Capecitabine has shown high efficacy in metastatic and adjuvant settings. This is a prospective, randomised trial, to compare the efficacy and safety profiles of capecitabine-containing regimen with non- capecitabine-containing…
- Trial name
- NCT01415336
- Testing
- Doxorubicin, Cyclophosphamide, doxorubicin, Capecitabine
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone…
- Trial name
- EarLEE-2 (NCT03081234)
- Testing
- Ribociclib, Adjuvant endocrine therapy
- Sponsor
- Novartis Pharmaceuticals
Metastatic Melanoma, Metastasis to Brain
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal…
- Trial name
- NCT05704933
- Testing
- Nivolumab, Ipilimumab, Nivolumab + Relatlimab
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Missing Teeth, Implants
Outcome of Dental Implant Therapy in Patients Treated With Antiresorptive Medication
Aim of the study is to examine the feasibility of dental implant insertion in patients receiving high, adjuvant and low dose > 4 years.
- Conditions
- Missing Teeth, Implants, Cancer, Osteoporosis
- Trial name
- NCT04741906
- Testing
- Dental implant surgery, Prosthetic treatment
- Where
- Denmark
- Volunteers
- 225 people
- Sponsor
- Copenhagen University Hospital at Herlev
Colon Cancer Stage
Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer
The study aimed at evaluation of anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer
- Trial name
- NCT03645187
- Testing
- FOLFERI, Folferi and celecoxib
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sherief Abd-Elsalam
Colorectal Cancer
Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00085163
- Testing
- celecoxib, fluorouracil, leucovorin calcium
- Where
- 36 sites in Austria, Belgium and 1 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection…
- Trial name
- NCT05367687
- Testing
- Camrelizumab、Rivoceranib, Camrelizumab
- Where
- China
- Volunteers
- 251 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
HCC
Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma
Radiofrequency ablation is a popular treatment for recurrent hepatocellular carcinoma (HCC),but still has a higher recurrence. Sorafenib as neo-adjuvant therapy in combination of RFA was not reported yet.
- Trial name
- ESCALATOR (NCT03097848)
- Testing
- RFA, Sorafenib
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Southwest Hospital, China
Parkinson's Disease
Effect of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease
This study aims to investigate the possible efficacy and safety of synbiotic preparation of Lactobacillus acidophilus probiotic with prebiotic fibers as an adjuvant therapy in the treatment of Parkinson's disease
- Trial name
- NCT05576818
- Testing
- Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Tanta University
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor…
- Trial name
- NCT06065748
- Testing
- Giredestrant, Fulvestrant, Abemaciclib
- Where
- 311 sites in United States, Argentina and 35 more
- Volunteers
- 1,050 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
The Synergism Or Long Duration (SOLD) Study
The purpose of the study is to compare disease-free survival (DFS) of women treated with concomitant trastuzumab plus docetaxel followed by FEC to that of the women treated with the same regimen followed by single-agent…
- Trial name
- SOLD (NCT00593697)
- Testing
- trastuzumab (9 weeks) + docetaxel, trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)
- Where
- Finland
- Volunteers
- 2,168 people
- Sponsor
- Finnish Breast Cancer Group
Diabetes Mellitus Type II
Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II
This is a pilot study to investigate the effect of e.-coli-nissle as supporting therapy to antidiabetic standard care in patients with diabetes mellitus type II
- Trial name
- PUNiDIA (NCT02144948)
- Testing
- e.-coli-nissle
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- GWT-TUD GmbH
Osteosarcoma
A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma
This is a Phase 1+2, open-label, dose-escalation, and multidose study, aiming to investigate the safety, tolerability and pharmacokinetics of ZKAB001 (a fully human monoclonal antibody targeting the Programmed Death - Ligand 1…
- Trial name
- NCT03676985
- Testing
- ZKAB001 5mg/kg, ZKAB001 10mg/kg, ZKAB001 15mg/kg
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Lee's Pharmaceutical Limited
Neo-adjuvant Short Course Chemo-radiotherapy in Locally Advanced Cancer Rectum
Neo-adjuvant Short Course Chemo-radiation Therapy in Locally Advanced Rectal Cancer Patients
The primary objective of this trial is to assess the safety and feasibility of 5-FU when given concurrently with5 Gy x 5 fractions IMRT.
- Trial name
- NCT04370418
- Testing
- short course chemo-radiation with 5-fluorouracil
- Where
- Egypt
- Volunteers
- 8 people
- Sponsor
- Assiut University
Bone Density
ATAC - Bone Density Sub-Protocol
To assess and quantify the changes in bone mineral density between the ARIMIDEX and ARIMIDEX plus NOLVADEX groups when compared to the NOLVADEX alone treatment group whilst receiving trial therapy.
- Trial name
- NCT00784940
- Testing
- Anastrozole, Tamoxifen
- Volunteers
- 308 people
- Sponsor
- AstraZeneca
Ovarian Cancer, Liquid Biopsy
Setting Up ctDNA Analysis on Archived Plasma Samples
This study (DARE part 1) is a single-center, retrospective, observational feasibility study promoted by the Fondazione Policlinico Universitario Agostino Gemelli IRCCS and co-funded by Fondazione AIRC, aimed at evaluating the…
- Trial name
- DARE-part1 (NCT07546578)
- Testing
- ctDNA
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cervical Cancer
Comparison of Different Subsequent Treatments After Radical Surgery
Cervical cancer is still the most common gynecologic cancer. There was no obvious increase of the survival over years. The risk of recurrence after radical surgery has increased with positive lymph nodes, positive surgical…
- Trial name
- STARS (NCT00806117)
- Testing
- Radiotherapy (RT), Concurrent chemoirradiation (CCRT), Sequence chemotherapy and radiotherapy (SCRT)
- Where
- China
- Volunteers
- 1,080 people
- Sponsor
- Sun Yat-sen University
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00363584
- Testing
- capecitabine, clinical observation, adjuvant therapy
- Where
- 46 sites in United Kingdom
- Volunteers
- 360 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.